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Abstract 15	
Histamine intolerance is a disorder in the homeostasis of histamine due to a reduced 16	
intestinal degradation of this amine, mainly caused by diamine oxidase (DAO) enzyme 17	
deficiency, which provokes its accumulation in plasma and the appearance of adverse 18	
health affects. A new approach for the diagnosis of this intolerance could be the 19	
determination of histamine and its metabolites in urine. The aim of this work was to 20	
develop and validate a rapid method to determine histamine and methylhistamine in 21	
human urine by Ultra High Performance Liquid Chromatography and Fluorimetric 22	
detection (UHPLC-FL). The proposed method is a consistent procedure to determine 23	
histamine and methylhistamine in less than 11 minutes with adequate linearity and 24	
sensitivity. Relative standard deviation was always lower than 5.5%, ensuring method 25	
precision; and mean recovery was greater than 99% for both analytes. The structure of 26	
histamine and methylhistamine conjugated with OPA were confirmed by UHPLC-ITD-27	
FTMS which enabled to unequivocally identify both analytes in standards and also in 28	
urine samples. The analysis of histamine and methylhistamine in urine samples could be 29	
a potential new approach for the routine diagnosis of histamine intolerance, more 30	
patient-friendly and with clear advantages in terms of equipment and personnel 31	
demand for sample collection in comparison with current plasmatic DAO activity 32	
determination. 33	
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1. Introduction 38	
Histamine (2-[4-imidazolyl]ethylamine) is a bioactive amine discovered in 1910 by Dale 39	
and Laidlaw [1] which is synthesized by decarboxylation of the amino acid histidine, 40	
using pyridoxal phosphate (vitamin B6) as cofactor. It is mainly produced in mast cells, 41	
basophils, platelets, histaminergic neurons and enterochromaffin cells; where it is 42	
stored intracellularly in vesicles until its release upon stimulation. Histamine (HA) is 43	
involved in the regulation of different physiological functions such as the secretion of 44	
gastric juice, cell growth and cellular differentiation, the day-night rhythm, 45	
neurotransmission and immunomodulation [2,3]. 46	
Two metabolic pathways for HA are known in humans. Histamine-N-methyltransferase 47	
(HNMT) is the enzyme responsible for the ring methylation of HA and is mainly located 48	
in the liver and kidney and it carries out the conversion of HA to 1-methylhistamine 49	
(MHA), which will be finally converted to N-methylimidazoleacetic acid. As a cytosolic 50	
protein, HNMT metabolizes HA only in the intracellular space of cells [4-6]. On the other 51	
hand, diamine oxidase (DAO) is an enzyme of mainly intestinal location that performs 52	
the oxidative deamination of HA producing imidazole acetaldehyde, which will later be 53	
converted to imidazoleacetic acid and finally combined with ribose for its urinary 54	
excretion. As a secretory protein, DAO is responsible for scavenging extracellular HA 55	
after mediator release, being the main enzyme for the metabolism of intestinal HA [4-56	
6]. 57	
Histamine intolerance (HIT) is a disorder in the homeostasis of HA due to a reduced 58	
intestinal degradation of this amine resulting in its accumulation in plasma and the 59	
appearance of multi-faced clinical symptoms, mainly headaches, flatulence, diarrhea, 60	
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abdominal pain, sneezing, rhinorrhea, hypotonia, arrhythmias, idiopathic urticaria and 61	
pruritus [2,3,7]. An enzymatic deficiency of DAO, key enzyme in the intestinal 62	
degradation of histamine, can occur based on genetic predisposition, in inflammatory 63	
and degenerative intestinal disorders or by pharmacological blockade [3,8,9]. The 64	
incidence of HIT has been estimated to be 1% of the population although this percentage 65	
may increase as a consequence of a better knowledge and diagnostic of this enzymatic 66	
deficiency. Current therapy for HIT is the limitation of foods containing HA, which may 67	
be complemented with encapsulated DAO enzyme to contribute to the degradation of 68	
intestinal HA [3,10]. 69	
Currently, the identification of individuals with HIT is based on plasmatic DAO activity 70	
through a biochemical assay that measures the amount of HA that can be degraded by 71	
this enzyme [11]. An alternative for the diagnosis of HIT by DAO deficiency could be the 72	
determination of HA and its metabolites in urine, considering that individuals with 73	
insufficient DAO activity would have a distribution profile of these compounds 74	
significantly different from healthy individuals. In fact, individuals with symptoms 75	
associated with HIT would show a higher urinary content of HA and its major metabolite 76	
produced by the HNMT metabolic pathway (MHA) than healthy population. 77	
The analytical approach for the simultaneous determination of HA and its metabolites 78	
is complex. There are commercial kits that allow the determination of HA through ELISA 79	
and of its metabolites through radioimmunoassay (RIA) techniques. However, these 80	
immunological-based techniques do not allow simultaneous determination of HA and 81	
its metabolites, while, in the case of RIA, they also involve complications related to the 82	
use of radioactive material [12]. Alternatively, chromatographic methods, mainly based 83	
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on high performance liquid chromatography (HPLC) coupled with various detection 84	
systems, appear to be the most appropriate for the simultaneous separation and 85	
quantification of these compounds [13]. Few HPLC methods are available in the 86	
literature for the simultaneous determination of HA and MHA, mainly focused on the 87	
quantification of both compounds in laboratory animal plasma and other biological 88	
specimens, such as brain or intestinal tissues [14-19]. Although UV detection has been 89	
widely used, the high sensitivity and specificity necessary to detect these compounds in 90	
samples such as blood makes fluorescence (FL) or mass spectrometry (MS) detection 91	
systems more suitable for this purpose. More recently, ultra high performance liquid 92	
chromatography (UHPLC) has been proposed for the simultaneous determination of HA 93	
and MHA in mice hair and cerebrospinal fluid [20-22]. A fast chromatographic procedure 94	
(UHPLC) coupled with FL detection could be an advantageous approach for the routine 95	
determination of these analytes in human urine. 96	
In order to have a new approach for the diagnosis of histamine intolerance, the aim of 97	
this work was to develop and validate a rapid and reliable method to quantifity HA and 98	
MHA in urine. An UHPLC procedure coupled with an on-line ο-phthaldehyde (OPA) post-99	
column derivatization and FL detection has been validated in terms of linearity, 100	
sensitivity, precision and recovery. Structural analysis of HA and MHA OPA derivatives 101	
using UHPLC-ITD-FTMS was carried out to unequivocally identify these compounds in 102	
urine samples. 103	
 104	
2. Material and methods 105	
2.1. Reagents and chemicals 106	
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Histamine dihydrochloride and 1-methylhistamine dihydrochloride were purchased 107	
from Sigma (St. Louis, MO, USA). Ultra pure water (18.2 MΩcm) was produced using a 108	
LaboStar System from Evoqua Water Technologies (Warrendale, PA, USA). Methanol 109	
and acetonitrile (both HPLC grade) were obtained from Fisher Scientific (Loughborough, 110	
UK). The other reagent-grade chemicals used were: acetic acid, formic acid, sodium 111	
acetate anhydrous, OPA, 2-mercaptoethanol and Brij 35 from Merck (Darmstadt, 112	
Germany); hydrochloric acid 0.1M (HCl), potassium hydroxide, boric acid and 113	
ammonium 30% from Panreac (Barcelona, Spain); and sodium octanesulphonate from 114	
Romil Chemicals (Cambridge, UK). 115	
 116	
2.2. Standard solutions 117	
Stock solutions of HA and MHA were prepared in 0.1 M HCl for a given concentration of 118	
20 mg/L. Pooled working standard solutions (ranging from 0.05 to 10 mg/L) were 119	
prepared diluting and mixing aliquot of each compound stock solution with 0.1 M HCl. 120	
Standard solutions were protected from light and stored at 4°C until use and filtered 121	
through a 0.22 μm membrane filter (GHP, Waters Corp., Milford, MA, USA). 122	
 123	
2.3. Samples preparation and MCX SPE procedure 124	
Urine samples from twelve subjects aged 22-40 years were collected for 24 hours 125	
without the addition of preservatives. All volunteers received an information kit, 126	
including an informed consent form and a questionnaire to record any symptomatology 127	
associated with HIT. Samples were stored in a freezer (-20 °C) until analysis. Prior to 128	
experiments, samples were thawed at room temperature and completely homogenized. 129	
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Sample preparation consisted of an acidic hydrolysis by adding 750 μL of 0.1 M HCl to 130	
10 mL of urine sample. The solution was placed in a heater at 90 °C for 30 minutes and 131	
subsequently cooled at room temperature. Later, a purification and concentration 132	
procedure was performed by solid phase extraction (SPE) using mixed cation exchange 133	
(MCX, 3 mL, 60 mg) cartridges acquired from Waters Corporation (Milford, MA, USA). 134	
The cartridges were conditioned with 2 mL of methanol, followed by 2 mL of distilled 135	
water. After adsorption of the sample, the cartridge was washed with 10 mL of 0.1 M 136	
HCl and dried for 1 minute under vacuum to remove the excess of water. The elution of 137	
HA and MHA was performed with 2 mL of 5% NH4OH in methanol (v/v). The eluate was 138	
evaporated to dryness with a centrifugal vacuum concentrator (30 °C, 1465 rpm) and 139	
later redissolved in 200 μL of 0.1 M HCl and filtered through a 0.22 μm filter (GHP, 140	
Waters Corp., Milford, MA, USA) before UHPLC injection. 141	
 142	
2.4. UHPLC-FL determination of HA and MHA 143	
2.4.1. Equipment 144	
Chromatographic separation was performed using an UHPLC-FL system consisting of a 145	
Waters Acquity™ Ultra Performance Liquid Chromatography equipment, which involved 146	
a quaternary pump, an auto-sampler and a FL detector; accomplished with a post-147	
column reagent manager (Waters 510). The post-column pump was connected to a zero 148	
dead volume installed between the column outlet and the detector. An Acquity UPLC™ 149	
BEH C18 column (1.7 μm, 2.1 mm x 50 mm) (Waters Corp., Milford, MA, USA) was used 150	
as the analytic column. Data acquisition was managed with the Empower version 3 151	
system. 152	
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 153	
2.4.2. Chromatographic conditions 154	
Mobile phase consisted of the eluent A as a solution of 0.1 M sodium acetate and 10 155	
mM sodium octanesulphonate adjusted to pH 4.8 with acetic acid, and the eluent B as 156	
a mixture of solvent B-acetonitrile (6.6:3.4), where solvent B was a solution of 0.2 M 157	
sodium acetate and 10 mM sodium octanesulphonate adjusted to pH 4.5 with acetic 158	
acid. The mobile phase was filtered through a 0.22 μm filter. The flow rate of the mobile 159	
phase was 0.8 mL/min. A linear gradient was applied: 0 min, 80% A; 6 min, 70% A; 6.5 160	
min, 0% A; 8.5 min 0% A; 9 min, 80% A. Finally, the system was re-equilibrated for 2 min 161	
at the initial conditions before the next injection. Derivatization reagent was prepared 162	
by mixing and aqueous solution of 31 g of boric acid and 26.2 g of potassium hydroxide 163	
with 0.2 g of OPA dissolved in 5 mL of methanol. To the above solution, 3 mL of 30% Brij 164	
and 3 mL of 2-mercaptoethanol as a reducing agent were added and final volume was 165	
brought to 1 L with water. The daily prepared post-column derivatization reagent was 166	
filtered through a 0.22 μm membrane filter and protected from light. The flow rate of 167	
the derivatization reagent was 0.4 mL/min. Automatic injection of 1 μL of the standard 168	
solution and samples was carried out. Vials filled with standard solutions or samples 169	
were cooled to 4 °C in the auto sampler, the column was kept at 42 °C and post-column 170	
reaction equipment was mantained at room temperature. Fluorescence detection at 171	
340 nm for excitation and 445 nm for emission was applied. 172	
 173	
2.5. LC-MS system 174	
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An LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, Hemel Hempstead, UK) 175	
equipped with an ESI source working in positive mode was used for accurate mass 176	
measurements. Mass spectra were acquired in profile mode with a setting of 30,000 177	
resolution at m/z 400. Operation parameters were as follows: source voltage, 3.5kV; 178	
sheath gas, 50 (arbitrary units); auxiliary gas, 20 (arbitrary units); sweep gas, 2 (arbitrary 179	
units); and capillary temperature, 375 °C. Default values were used for most other 180	
acquisition parameters (FT Automatic gain control (AGC) target 5 · 105 for MS mode and 181	
5 · 104 for MSn mode). Samples were analysed in full scan mode at a resolving power of 182	
30,000 at m/z 400 and MS2 events acquired at a resolving power of 15,000. An isolation 183	
width of 1 amu was used and precursors were fragmented by collision-induced 184	
dissociation C-trap (CID) with normalised collision energy of 35 V and an activation time 185	
of 10 ms. The mass range in FTMS mode was from m/z 100 to 1000. Data analysis was 186	
achieved using XCalibur software v2.0.7 (Thermo Fisher Scientific). An external 187	
calibration for mass was carried out before the analysis.  188	
Liquid chromatography analysis was performed using an Accela chromatograph 189	
(Thermo Scientific, Hemel Hempstead, UK) equipped with a quaternary pump and a 190	
thermostated autosampler. Chromatographic separation was accomplished with an 191	
Acquity UPLC™ BEH C18 column (1.7 μm, 2.1 mm x 50 mm) (Waters Corp., Milford, MA, 192	
USA) kept at 40 °C. The mobile phase consisted of 0.1% formic acid in water (solvent A) 193	
and 0.1% formic acid in acetonitrile (solvent B), and was delivered at a constant flow 194	
rate of 0.8 ml/min following a gradient elution: 0 min, 100% A; 3 min, 80% A and 20% B; 195	
3.5 min, 80% A and 20% B; 3.6 min 40% A and 60% B; 4.6 min, 40% A and 60% B; 5 min, 196	
100% A. Finally, the system was re-equilibrated for 2 min at the initial conditions before 197	
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the next injection. The autosampler plate was held at 10 °C and the injection volume 198	
was 1 μL. 199	
For the pre-column derivatization, 2% acid formic in water was used for the preparation 200	
of standard solutions and to resuspended urine samples. To 100 μL of standard solution, 201	
or redissolved urine sample, 400 μL of the derivatization reagent were added and 202	
thoroughly mixed using a vortex. UHPLC-MS analysis was performed immediately after 203	
the derivatization reaction due to the low stability of OPA derivatives. 204	
 205	
2.6. Statistical analysis 206	
The statistical analysis of data was performed with Statistical Software Package for 207	
Windows SPSS, version 22 (SPSS, Chicago, IL, USA). Analysis of the variance for linear 208	
regression was used to test the reliability of the method. The Student’s t-test was used 209	
to compare between data sets and the homogeneity of variances was assessed through 210	
Cochran’s C test. 211	
 212	
3. Results and discussion 213	
To properly determine total content of HA and MHA in urine, sample preparation 214	
consisted in the acid hydrolysis (0.1M HCl) combined with heat treatment. As reported 215	
in previous works, higher levels of these compounds were obtained in hydrolysed urine 216	
than in non-hydrolysed samples [17]. In order to set final sample hydrolysis parameters, 217	
several time and temperature conditions were assayed. Total conversion of conjugated 218	
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analytes to free HA and MHA was achieved after submitting the sample at 90 °C for 30 219	
minutes. 220	
Purification and concentration procedure through MCX SPE cartridges was implemented 221	
attending the low concentration of HA and MHA in urine and the need to minimize 222	
potential interferences of this matrix. When loading urine sample onto the SPE 223	
cartridge, acid pH values achieved by previous acidic hydrolysis facilitated the strong 224	
interaction of positively charged amine groups of HA and MHA with the sulfonic anion 225	
of MCX sorbent. A proper cleanup step washing with 0.1M HCl allowed the reduction of 226	
matrix interferences. Later elution with a basic 5% NH4OH in methanol (v/v) solution 227	
ensured cleavage of the electrostatic interactions between ammonium ion of HA and 228	
MHA and sulfonic anion of the sorbent. The use of MCX SPE cartridges allowed five-fold 229	
pre-concentration of analytes and greater sample concentration was achieved by eluate 230	
evaporation to dryness with a centrifugal vacuum concentrator. Overall analytical 231	
procedure achieved a final concentration of the analytes of fifty-fold in relation to initial 232	
urine content. 233	
Due to the low natural fluorescence of the analytes, the use of a derivatizing reagent in 234	
order to detect HA and MHA and increase the sensitivity of the method was required. 235	
The presence of amino groups in the structures of HA and MHA makes both compounds 236	
suitable for the derivatization with a large number of fluorogenic reagents, being OPA, 237	
fluorescamina and DBD-F (4-(N,N-dimethylaminosulfonyl)-7-fluoro-2,1,3-238	
benzoxadiazole) the most commonly used [12,13,20]. In this method, an online post-239	
column OPA derivatization procedure was used, which ensured a high reproducibility by 240	
minimizing sample manipulation prior to the injection. Moreover, OPA reacts rapidly 241	
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with amines in the presence of a reducing agent, improving detection sensitivity, 242	
reducing the polarity of original amino compounds and increasing method selectivity 243	
[23]. The current method provides a significant improvement in comparison with some 244	
previous methods that mostly used pre-column derivatization techniques, which could 245	
face problems related to the low stability of OPA-amine derivatives [12,13]. 246	
According to previous methods, several mobile phase compositions and gradient 247	
programmes were assayed to get the best resolved peaks for HA and MHA [12,13,24]. 248	
Considering the slightly structural differences of the analytes, a mobile phase consisting 249	
in two eluents of different polarity and pH permitted to establish the necessary gradient 250	
in order to properly separate HA and MHA. This was achieved by a gradual and linear 251	
slight increase of eluent B, the less polar eluent of the mobile phase, during the first 252	
minutes of the chromatographic run. Just after the separation of both analytes, the 253	
proportion of acetonitrile was markedly incremented aiming to completely elute less 254	
polar urinary compounds, which consequently incremented the chromatographic run 255	
up to the final 11 minutes. Moreover, sodium octanesulphonate as ion-pairing reagent 256	
was added to the mobile phase in order to improve chromatographic separation of 257	
these hydrophilic and polar compounds. Fig. 1 shows the chromatograms of the 258	
standard solutions and of urine samples. The proposed method accomplished an 259	
acceptable separation between HA and MHA with a chromatographic resolution (R) of 260	
1.5. HA and MHA were identified on the basis of the retention time by comparison with 261	
the standard. 262	
The present UHPLC method reduces considerably the time required for urinary 263	
determination of HA and MHA in comparison with previously published HPLC-FL 264	
		 13 
methods, resulting in turn in decreased reagent costs and reduced environmental 265	
impact [14,15,17]. The reliability of this UHPLC method for routine analysis of urine 266	
samples was assessed in terms of linearity, sensitivity, precision and recovery. 267	
 268	
3.1. Linearity 269	
Linearity was tested at twelve different concentrations between 0.05 and 10 mg/L, 270	
performing seven measurements at each level. Analysis of the variance of the regression 271	
allowed assessing the linearity of the UHPLC method. Least-squares analysis resulted in 272	
a correlation coefficient of r≥0.9999 for both analytes (p<0.001). Calibrations data fit a 273	
linear regression model with determination coefficients (r2) higher than 99.99% for all 274	
standard curves. 275	
 276	
3.2. Sensitivity 277	
The chromatographic limit of detection (LOD) and the limit of quantification (LOQ) were 278	
obtained following the IUPAC guidelines and using low-concentration HA and MHA 279	
standard regression curves ranging from 0.05 to 0.8 mg/L [25]. A blank consisting in 0.1 280	
M HCl was used to determine baseline noise. LODs were 0.025 mg/L for HA and 0.028 281	
mg/L for MHA. LOQs were 0.035 mg/L and 0.045 mg/L for HA and MHA, respectively. To 282	
confirm the established LODs and LOQs a standard solution at those level 283	
concentrations was analysed (Table 1).  284	
 285	
3.3. Precision 286	
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Method precision was evaluated through repeatability by carrying out seven 287	
independent determinations of a urine sample from a volunteer using the same 288	
analytical conditions (Table 1). Urine and spiked urine with known amounts of HA and 289	
MHA (0.01, 0.04 and 0.15 mg/L) were studied in septuplicate in order to test the 290	
precision at different levels. The relative standard deviation (RSD) for HA and MHA at all 291	
concentration levels was lower than 5.5%, representing a satisfactory level of precision. 292	
The Horwitz equation for intra-laboratory studies confirmed the acceptability of these 293	
precision results. 294	
 295	
3.4. Recovery 296	
Method recovery was determined via accuracy evaluation by the standard addition 297	
procedure using urine samples spiked with three addition levels (0.01, 0.04 and 0.15 298	
mg/L of HA and MHA). Seven determinations were performed for each addition level 299	
(Table 1). The mean recovery of HA was 99.25% (SD=1.86), which was not statistically 300	
different from the theoretical value of 100% (p>0.005 according to the Student’s t-test). 301	
For MHA, mean recovery was 99.8% (SD=0.21), which neither was statistically different 302	
from the theoretical value of 100% (p>0.005). The assumption of homogeneity of 303	
variances among the three spiking levels was tested using Cochran’s C test. Experimental 304	
values for both analytes remained under the Cochran’s test tabled value, confirming 305	
that the variance of recovery values was not dependent on the analyte content 306	
(p>0.005). 307	
 308	
3.5. Structural analysis of HA and MHA OPA derivatives using UHPLC-HRMS 309	
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The structure of HA and MHA conjugated with OPA were confirmed by UHPLC-ITD-FTMS 310	
which enabled specific detection of both compounds in a complex matrix such as urine. 311	
The spectra showed the protonated molecule with a mass error of less than 2 ppm. 312	
The mass spectra shown in Fig. 3 and Fig. 4 confirmed that the OPA complex for HA was 313	
formed with a molecular ion [M+H]+ at m/z = 288.1162 (-1.2 ppm error) in the standard 314	
and a molecular ion [M+H] + at m/z = 288.1165 (0.0 ppm error) in the urine sample. For 315	
MHA, OPA conjugated complex was observed with a molecular ion [M+H] at m/z = 316	
302.1319 (-1.1 ppm error) and at m/z = 302.1318 (-0.8 ppm error) in the standard and 317	
urine sample, respectively. 318	
Moreover, injection in MS2 mode was performed. The MS2 spectra gave as result an ion 319	
with m/z 228.1132 for HA and an ion with m/z 242.1290 for MHA. Confirmation in 320	
samples was accomplished by injection of urine samples in the same conditions. Results 321	
are shown in Fig. 3 and Fig. 4. 322	
 323	
3.6. UHPLC-FL sample analysis 324	
Urine samples from twelve volunteers were analysed using the proposed method (Fig. 325	
2). No significant differences were found in HA urinary content from different volunteers 326	
with a mean value of 0.143 ± 0.08 μmol/day, which is in good agreement with the values 327	
obtained by other works [17,26]. On the contrary, greater differences in MHA content 328	
were found in analysed urine samples. Concretely, two individuals who reported 329	
symptomatology related to HIT showed a significantly higher urinary content of MHA. 330	
Moreover, the increased MHA contents exceeded the threshold established as normal 331	
level of this analyte in urine [27]. These results support the initial hypothesis according 332	
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to which the decrease in DAO activity would cause an accumulation of MHA, the 333	
metabolite produced by HNMT. Therefore, this method could be an advantageous and 334	
more patient-friendly alternative to current plasmatic DAO activity determination used 335	
to diagnose histamine intolerance, being less invasive and avoiding the need for specific 336	
equipment and qualified personnel required for plasma sample extraction. Additionally, 337	
the distribution profile of histamine and its main metabolite in urine could provide a 338	
complementary evaluation of DAO activity, specifically considering that some authors 339	
have reported a wide variability in DAO activity both in healthy volunteers and patients 340	
diagnosed with HIT according to their symptomatology [28,29]. 341	
 342	
4. Conclusion 343	
The proposed UHPLC method allows the satisfactory determination of urinary HA and 344	
MHA in less than 11 minutes. The use of MCX SPE cartridges was effective for the 345	
selective purification and concentration of HA and MHA in human urine. Overall sample 346	
treatment procedure achieved a final concentration of the analytes of fifty-fold in 347	
relation to initial urine content. Online post-column derivatization of the analytes with 348	
OPA permitted the sensitive detection of the analytes while minimizing sample 349	
manipulation prior to UHPLC injection. Unequivocal identification of HA and MHA OPA 350	
derivatives in standard and in urine samples has been accomplished through UHPLC-351	
ITD-FTMS. To our knowledge, this is the first UHPLC-FL method with OPA post-column 352	
derivatization used to determine HA and MHA in human urine; thus becoming a 353	
potential new approach for the routine diagnosis of histamine intolerant individuals. 354	
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Further studies involving more volunteers are needed to validate MHA as a biomarker 355	
for the diagnosis of HIT. 356	
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Fig 1. Chromatograms of HA and MHA standard solution of 10 mg/L (A) and a urine 458	
sample (B). 459	
Fig 2. Urinary content of HA and MHA (μmol/day) in twelve volunteers. Dashed lines 460	
indicate normal levels of HA and MHA reported by literature. 461	
Fig 3. Representative chromatogram, FTMS spectra and MS2 spectra of OPA derivative 462	
HA (A) and MHA (B) standars. 463	
Fig 4. Representative chromatogram, FTMS spectra and MS2 spectra of OPA derivative 464	
HA (A) and MHA (B) in a urine sample.  465	
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Table 1. Summary of validation results. 466	
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